Technological Innovation and Social Commitment
ADmit Therapeutics S.L. is a pioneering company in the application of innovative technologies in the field of neurodegenerative diseases, with a strong social component. Its main asset is a highly trained team with experience in medical diagnostics, neurobiology, artificial intelligence, and the development and marketing of medical devices. Its quality is demonstrated by the clearance of the manufacturing license from the Spanish Agency of Medicines and Medical Devices (AEMPS), the ISO 13485 certification, the laboratory accreditation from the College of American Pathologists (CAP), and the Clinical Laboratory Improvement Amendments (CLIA) certificate, becoming the first Spanish CAP/CLIA laboratory.
The MAP-AD® Test is certified with the CE Mark under the In Vitro Diagnostic Regulation (IVDR, EU 2017/746), ensuring that the test complies with the European Union’s strict safety and performance standards. In addition to the development and commercialization of the MAP-AD®, the company continues to work on incorporating new solutions in the field of neurodegenerative diseases to improve the quality of life for patients and their families.



Innovation
Our team has an innovative vision that has allowed us to develop a disruptive approach to the market.
Efficiency and Effectiveness
We optimize our resources to achieve each of our scientific and business objectives.
Agility
We adopt agile and solid decisions to achieve our goals within the agreed timeframe.


A crucial step towards personalized medicine
The MAP-AD® test provides a prognosis for the progression from Mild Cognitive Impairment to Alzheimer’s Disease Dementia. This solution links disease biology, mitochondrial dysfunction, with cognitive changes. This is achieved through the analysis of novel blood biomarkers, mitochondrial DNA methylation, along with key disease risk factors (ApoE genotype and age), and neuropsychological assessment. Predicting cognitive decline years in advance opens the door to earlier interventions and optimizes patient selection for clinical trials, representing a significant advance in personalized and precision medicine.
Lastest news
- November 16, 2026
Our company presents the MAP-AD® prognostic test at RASEN 2026
Barcelona (Spain), November 17, 2026. We are currently participating in RASEN26 in Sevilla (Barceló Convention Center), a benchmark event for the advancement of neurology and clinical innovation. Throughout the congress, our team is welcoming attendees at our booth located in the Polo Tecnológico to showcase the capabilities of the MAP-AD® test. MAP-AD® is a CE-IVDR marked prognostic blood tool designed […]
- November 16, 2026
We are at MEDICA 2026 presenting MAP-AD®, our prognostic test for Alzheimer’s Dementia
Barcelona (Spain), November 16, 2026. We are already present at MEDICA2026, the leading international event for the medical and healthcare technology sector. Throughout the exhibition, our team is welcoming professionals and strategic partners at Hall 1, Booth D33 to present the MAP-AD® test in detail. MAP-AD® is a CE-IVDR marked prognostic blood test designed to predict the progression of Mild […]
- November 4, 2026
ADmit Therapeutics presents the MAP-AD Test at the 13th Argentine Congress of Clinical Laboratory Quality (CALILAB 2026)
Barcelona (Spain), November 4, 2026. ADmit Therapeutics will participate in the Neurogenetics Conference organized by MANLAB within the framework of the 13th Argentine Congress of Clinical Laboratory Quality (CALILAB 2026). Dr. Carla Trapero will present the MAP-AD Test, the only regulatory-approved blood-based prognostic test (IVDR – EU 2017/746) that predicts progression to Alzheimer’s dementia in patients with mild […]
Team
Members of the Board of Directors
Ferran
Prat
Chairman of the Board of Directors
Marta Barrachina
Co-Founder
CEO
Santiago Lozano
Board of
Directors
Maite
Fibla
Board of
Directors




This project has received funding from the European Union’s H2020 research and innovation program under number 960327.